Clinical Trial Update: Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for dalantercept in recurrent ovarian, fallopian tube, or primary peritoneal cancer; study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Peritoneal Cancer

Drugs mentioned

• dalantercept (dalantercept)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-12-08